An Intracerebral Hemorrhage Care Bundle Is Associated with Lower Case Fatality.
Adrian R Parry-Jones, Camilla Sammut-Powell, Kyriaki Paroutoglou...
https://pubmed.ncbi.nlm.nih.gov/31291031/Actively Recruiting
Led by Region Skane · Updated on 2026-05-22
3500
Participants Needed
54
Research Sites
17 weeks
Total Duration
Spontaneous intracerebral hemorrhage ICH is a serious type of stroke with high death and disability rates. Researchers are investigating whether a structured treatment package called a Care Bundle can improve the 3-month outcomes for patients with acute ICH compared to standard care. The study is an international, multicenter, parallel, cluster-randomized clinical trial focusing on implementing this Care Bundle in high-income countries, building on results from previous trials mostly done in low- and middle-income countries. The Care Bundle includes early intensive blood pressure lowering, treatment of fever and high blood sugar, rapid reversal of oral anticoagulation, and timely referrals to intensive care or neurosurgery when needed. Hospitals are randomized in batches through three phases usual care, randomized evaluation of the Care Bundle versus usual care, and a post-implementation follow-up where all hospitals apply the Care Bundle. Each batch lasts 18 months, with 6 months per phase, and the overall study rollout spans 2.5 years. Participants are adults aged 18 or older diagnosed with spontaneous ICH confirmed by imaging within 24 hours of symptom onset. During the study, patient management details and outcomes will be closely monitored, including brain imaging, blood pressure, glucose levels, and functional status. The primary outcome is functional recovery measured by a utility-weighted modified Rankin Scale score at 180 days. Secondary outcomes include disability, death, and health-related quality of life. The study also collects data on treatments and care decisions to evaluate the Care Bundles effectiveness and sustainability.
CONDITIONS
International Care Bundle Evaluation in Cerebral Hemorrhage Research
T
Teresa Ullberg, MD, PhD
T
Trine Apostolaki-Hansson, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Region Skane
Lead Sponsor
The George Institute for Global Health, Australia
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Care bundle as tested in trial | Usual care as delivered in trial | Guideline‑recommended acute ICH bundle |
|---|---|---|---|
| What it is | A structured bundle of acute treatments including anticoagulation reversal, prompt blood pressure control, fever and glucose management, avoiding early DNR orders, rapid ICU/neurosurgery referral, and repeat imaging as needed | Management decisions such as monitoring, investigations, blood pressure lowering, fluids, glycemic control, ventilation, neurosurgery, and support made at treating team’s discretion | An organized acute ICH care bundle recommended by recent guidelines including timely blood pressure lowering, anticoagulation reversal, fever and glucose control, and structured stroke unit or critical care admission |
| Role in the trial | Randomized intervention arm receiving the care bundle | Randomized control arm receiving usual care by clinical team | Represents structured care now advocated but not randomized in the trial |
| Primary use in clinical decision | To test whether structured implementation of acute interventions improves outcomes in acute ICH | To represent current routine management practices for ICH patients | Represents an evidence‑based acute care model now recommended in guidelines |
| How it is performed | Delivered as a predefined bundle within 30 minutes of diagnosis including reversal agents, BP targets, temp and glucose targets, referral actions, and repeat imaging | Treatment and investigations decided and delivered per treating clinician judgement without mandated protocol | Following guideline‑recommended protocolized acute management delivered by organized stroke or critical care systems |
| Evidence status | Effectiveness not yet established—trial ongoing | Represents current unstandardized care with variable evidence | Supported by guidelines and expert consensus for reducing mortality and improving outcomes |
| Important risks | Risks not fully assessed yet since trial is ongoing | Risk profile reflects variable routine care practices | No major new risks identified beyond standard critical care procedures |
| Important limitations | Trial is cluster‑randomized and results may depend on center capability to deliver bundle quickly | Variable practices across centers may limit comparisons | Implementation in real‑world settings may require resources and system coordination |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to hospital discharge or death
Participants receive a Care Bundle involving early intensive blood pressure lowering, reversal of oral anticoagulation, treatment of pyrexia and hyperglycemia, and referral to intensive care or neurosurgery as needed. Participants in the usual care group receive standard clinical management as decided by their treating team.
Continuous monitoring during hospital stay with treatment applied as part of routine care
Duration - Approximately 6 months (180±30 days)
Participants are followed up to assess functional outcomes and quality of life approximately 6 months after intracerebral hemorrhage.
1 to 2 visits depending on follow-up assessments
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Adrian R Parry-Jones, Camilla Sammut-Powell, Kyriaki Paroutoglou...
https://pubmed.ncbi.nlm.nih.gov/31291031/D B Zahuranec, D L Brown, L D Lisabeth...
https://pubmed.ncbi.nlm.nih.gov/17502545/Trine Apostolaki-Hansson, Menglu Ouyang, Dar Dowlatshahi...
https://pubmed.ncbi.nlm.nih.gov/40356012/Lili Song, Xin Hu, Lu Ma...
https://pubmed.ncbi.nlm.nih.gov/34930428/Charlotte Jj van Asch, Merel Ja Luitse, Gabriël Je Rinkel...
https://pubmed.ncbi.nlm.nih.gov/20056489/GBD 2019 Stroke Collaborators
https://pubmed.ncbi.nlm.nih.gov/34487721/K J Becker, A B Baxter, W A Cohen...
https://pubmed.ncbi.nlm.nih.gov/11274312/J Claude Hemphill, Jeffrey Newman, Shoujun Zhao...
https://pubmed.ncbi.nlm.nih.gov/15044768/A I Qureshi, S Tuhrim, J P Broderick...
https://pubmed.ncbi.nlm.nih.gov/11346811/Region Skane
Lead Sponsor
The George Institute for Global Health, Australia
Collaborating Sponsor